UroGen Pharma Ltd. — 2017 Form 20-F Summary
Business context and reporting period. This audited annual report covers the fiscal year ended December 31, 2017; it is not a quarterly report, and the filing does not provide standalone fourth-quarter results. UroGen is an Israeli clinical-stage biopharmaceutical company developing local therapies for urological cancers. Its lead candidates, MitoGel (UGN-101) and VesiGel (UGN-102), are sustained-release formulations of mitomycin C. The financial statements are prepared under U.S. GAAP in U.S. dollars.
Financial performance and position
| Metric | 2017 | 2016 |
|---|---|---|
| Revenue | $8.2 million | $17.5 million |
| Gross profit | $7.6 million | $17.5 million |
| Research and development expense, net | $18.7 million | $10.3 million |
| General and administrative expense | $8.8 million | $6.4 million |
| Operating income (loss) | $(20.0) million | $0.8 million |
| Net income (loss) | $(20.0) million | $(1.9) million |
| Basic and diluted loss per share | $(2.14) | $(1.91) |
| Operating cash flow | $(9.6) million | $4.2 million |
- Revenue was collaboration-related, not product sales: it included a $7.5 million Allergan milestone in 2017 and RTGel supply revenue. In 2016, UroGen recognized the $17.5 million Allergan upfront license fee. UroGen had no approved products or material product-sale revenue.
- Gross margin was approximately 92.6% in 2017, based on reported revenue and cost of revenue. The 2017 loss reflected increased development spending and lower collaboration revenue.
- R&D expense rose $8.4 million, principally due to MitoGel Phase 3 trial costs, share-based compensation, and increased staffing and clinical support. Total share-based compensation was $6.3 million, versus $2.0 million in 2016.
- Cash and cash equivalents were $37.0 million and short-term investments were $36.0 million at year-end, totaling $73.0 million. Working capital was $67.4 million; total assets were $75.6 million, liabilities $7.0 million, and shareholders’ equity $68.5 million. Accumulated deficit was $47.2 million.
- Investing cash outflow was $36.4 million, primarily from purchases of short-term investments. Financing provided $61.6 million, mainly from the May 2017 IPO, which generated approximately $60.8 million net proceeds. The filing reports no off-balance-sheet arrangements and no borrowings; reported liabilities were principally accrued expenses and deferred revenue.
- In January 2018, after year-end, the company raised approximately $64 million net from an offering of ordinary shares. This subsequent financing is not included in the December 31, 2017 cash balance.
Material changes versus the prior comparable year
- Revenue fell $9.3 million as the 2016 upfront Allergan payment exceeded the 2017 milestone and supply revenue.
- Operating results shifted from $0.8 million operating income in 2016 to a $20.0 million operating loss in 2017; net loss increased from $1.9 million to $20.0 million.
- Operating cash flow moved from $4.2 million provided in 2016 to $9.6 million used in 2017, reflecting lower collaboration receipts and higher operating expenditures.
- Year-end cash, cash equivalents and short-term investments increased to $73.0 million from $21.4 million, supported by the IPO and the Allergan milestone. Short-term investments were $36.0 million at year-end 2017 versus none reported at year-end 2016.
- The May 2017 IPO and conversion of preferred shares and warrants resulted in 13,751,390 ordinary shares outstanding at December 31, 2017, compared with 2,305,743 a year earlier.
Outlook, management commentary and key risks
- Management expected existing year-end resources to fund operating and capital requirements for at least 12 months from the filing’s assessment, while warning that additional capital would be needed to complete development and pursue commercialization. The January 2018 offering subsequently added approximately $64 million net.
- MitoGel was in a single-arm pivotal Phase 3 trial for low-grade upper tract urothelial carcinoma (UTUC), with planned enrollment of approximately 74 patients. Management expected, subject to successful trial completion and regulatory review, to submit an NDA in the first quarter of 2019.
- For VesiGel, management planned to file a U.S. IND in the first half of 2018 and, if accepted, begin a U.S. Phase 2b trial. These are forward-looking expectations, not assured outcomes.
- Early evidence is preliminary: the MitoGel compassionate-use program was small and lacked a uniform protocol and independent monitoring. In the VesiGel Phase 2a high-dose group, 19 of 22 patients achieved a complete response at the primary evaluation; the filing cautions that trial results may not predict later outcomes.
- Adverse events reported across programs included urinary irritation and pain, rash, allergy, flank pain, kidney swelling or infection, and transient laboratory changes in renal or blood measures. The filing also describes serious events in early studies, with many considered unrelated to treatment; larger trials may reveal additional safety issues.
- UroGen had not obtained regulatory approval for any candidate. Key risks include clinical-trial failure or delay, FDA disagreement with trial design or the proposed 505(b)(2) pathway, manufacturing and CMC validation, reimbursement and adoption, competition, and the need for further financing.
- Supply and collaboration risks include reliance on single-source suppliers, including Teva for mitomycin C API, and Allergan’s right to terminate its agreement for convenience. The Allergan arrangement offers potential milestone payments of up to $200 million and low-single-digit royalties, but these are contingent and not assured.
- Israeli Innovation Authority funding creates royalty and technology-transfer restrictions; approval may be needed for certain transfers or manufacturing outside Israel, with potentially significant repayment obligations. A stronger New Israeli Shekel could also increase U.S.-dollar operating costs.
- The company reported effective disclosure controls at December 31, 2017. As a newly public company, the annual report did not include management’s assessment or the auditor’s attestation on internal control over financial reporting.
Important facts for investors to verify
- Progress, enrollment, safety, efficacy and durability results from the MitoGel Phase 3 trial, and whether its single-arm design will support an NDA.
- Whether the VesiGel IND was accepted and the Phase 2b trial began, and whether its early response and durability findings are confirmed in U.S. studies.
- Actual cash burn, investment liquidity, and the period the post-January 2018 offering proceeds are expected to fund operations.
- Allergan’s development progress, any further milestone achievement, and the continued status and terms of the collaboration.
- Mitomycin C and other supply availability, manufacturing validation and CMC readiness, and any IIA approvals or payment exposure related to technology transfer.
- Any new safety signals, regulatory feedback, changes to development timelines, financing needs, or material changes in share count and potential dilution.